Cited by 429PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer TherapiesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Open access

Wander, Seth A., Hennessy, Bryan T., Slingerland, Joyce M.·2011·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathways gives us.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci44145

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165

Flagged first, then by citations

Show all 157 references

1 of the 157 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

Knowles, 2003, Cancer Res., 63, 7652
Chawla, 2006, J Clin Oncol., 24(suppl), 521s
Colombo, 2007, J Clin Oncol., 25(suppl), 278s
Slomovitz, 2008, J Clin Oncol., 26(suppl), 293s
Carracedo, 2008, J Clin Invest., 118, 3065
Chow LWC, et al. Presented at the 29th Annual San Antonio Breast Cancer Symposium (December 14–17, 2006, San Antonio, Texas, USA), Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer.
Shi, 2002, Cancer Res., 62, 5027

Sorted by citations

Items 101–200 of 429

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
Mortensen, D. S., Perrin-Ninkovic, S. M., Shevlin, G. I., Elsner, J., Zhao, J., Whitefield, B., Tehrani, L. R., Sapienza, J., Riggs, J. R., Parnes, J. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00627 · Cited by 75
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Kurani, H., Razavipour, S. F., Harikumar, K. B., Dunworth, M., Ewald, A. J., Nasir, A., Pearson, G. W., Booven, D. V., Zhou, Z., Azzam, D. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1299 · Cited by 73
Self-citation
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Werfel, T. A., Wang, S., Jackson, M. A., Kavanaugh, T. E., Joly, M. M., Lee, L., Hicks, D. J., Sanchez, V. M., Ericsson, P. I. G., Kilchrist, K. V., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2388 · Cited by 73
Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
Sayed, R. E., Jamal, L. E., Iskandarani, S. E., Kort, J., Salam, M. A., & Assi, H. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00510 · Cited by 75
Regulation of Endothelial Cell Proliferation and Vascular Assembly through Distinct mTORC2 Signaling Pathways
Wang, S., Amato, K. R., Song, W., Youngblood, V., Lee, K., Boothby, M. R., Brantley‐Sieders, D. M., & Chen, J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00306-14 · Cited by 70
Autophagy and tumorigenesis
Rangel, M., Kong, J., Bhatt, V. D., Khayati, K., & Guo, J. Y. (2021) · FEBS Journal · doi:10.1111/febs.16125 · Cited by 76
Pancreatic tumours escape from translational control through 4E-BP1 loss
Martineau, Y., Azar, R., Müller, D., Lasfargues, C., Khawand, S. E., Anesia, R., Pelletier, J., Bousquet, C., & Pyronnet, S. (2013) · Oncogene · doi:10.1038/onc.2013.100 · Cited by 69
mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain
Lisi, L., Aceto, P., Navarra, P., & Russo, C. D. (2015) · BioMed Research International · doi:10.1155/2015/394257 · Cited by 71
Cardiomyocyte autophagy and cancer chemotherapy
Li, D. ‘., & Hill, J. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.007 · Cited by 69
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
Lisi, L., Laudati, E., Navarra, P., & Russo, C. D. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-125 · Cited by 67
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency
Chang, M., Ma, T., Hung, C., Tian, Y., Chen, Y., Yang, C.-W., & Cheng, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-07300-x · Cited by 67
Non-canonical mTOR-Independent Role of DEPDC5 in Regulating GABAergic Network Development
Swaminathan, A., Hassan-Abdi, R., Renault, S., Siekierska, A., Riché, R., Liao, M., de Witte, P. A. M., Yanicostas, C., Soussi‐Yanicostas, N., Drapeau, P., et al. (2018) · Current Biology · doi:10.1016/j.cub.2018.04.061 · Cited by 70
The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways
Xu, M., Almasi, S., Yang, Y., Yan, C. W., Sterea, A. M., Syeda, A. K. R., Shen, B. Q., Clements, D. R., Huang, P., Gujar, S. A., et al. (2019) · Cell Calcium · doi:10.1016/j.ceca.2019.02.010 · Cited by 70
Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) In Human Cancer
Yu, Y., & Hann, S. S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221305 · Cited by 67
Emerging Therapeutics Targeting mRNA TranslationPreprint
Malina, A., Mills, J. R., & Pelletier, J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012377 · Cited by 68
PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 66
The structural basis for mTOR function
Baretić, D., & Williams, R. L. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.024 · Cited by 63
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
Sakre, N., Wildey, G. M., Behtaj, M., Kresak, A. M., Yang, M., Fu, P., & Dowlati, A. (2016) · Oncotarget · doi:10.18632/oncotarget.13362 · Cited by 64
Maintenance of Homeostasis in the Aging Hypothalamus: The Central and Peripheral Roles of Succinate
Chen, T. T., Maevsky, E. I., & Uchitel, M. L. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00007 · Cited by 62
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Wu, V. S., Kanaya, N., Lo, C., Mortimer, J. E., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.005 · Cited by 62
From kidney injury to kidney cancer
Peired, A. J., Lazzeri, E., Guzzi, F., Anders, H., & Romagnani, P. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.011 · Cited by 64
The Type 1 Insulin-Like Growth Factor Receptor (IGF-IR) Pathway Is Mandatory for the Follistatin-Induced Skeletal Muscle Hypertrophy
Kalista, S., Schakman, O., Gilson, H., Lause, P., Demeulder, B., Bertrand, L., Pende, M., & Thissen, J. (2011) · Endocrinology · doi:10.1210/en.2011-1687 · Cited by 60
Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds
Schulz, G., Victoria, C., Kirschning, A., & Steinmann, E. (2020) · Natural Product Reports · doi:10.1039/d0np00024h · Cited by 59
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
Simioni, C., Cani, A., Martelli, A. M., Zauli, G., Tabellini, G., McCubrey, J. A., Capitani, S., & Neri, L. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2490 · Cited by 60
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
Wander, S. A., Zhao, D., Besser, A. H., Hong, F., Wei, J., Ince, T. A., Milikowski, C., Bishopric, N. H., Minn, A. J., Creighton, C. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2389-6 · Cited by 58
Self-citation
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation
Akeno, N., Miller, A. L., Ma, X., & Wikenheiser‐Brokamp, K. A. (2014) · Oncogene · doi:10.1038/onc.2013.589 · Cited by 57
Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway
PATEL, S. R. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0316-6 · Cited by 57
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
Yun, S., Vincelette, N. D., Knorr, K. L. B., Almada, L. L., Schneider, P. A., Peterson, K. L., Flatten, K. S., Dai, H., Pratz, K. W., Hess, A. D., et al. (2016) · Blood · doi:10.1182/blood-2015-02-629485 · Cited by 55
Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing
Bettedi, L., & Foukas, L. C. (2017) · Biogerontology · doi:10.1007/s10522-017-9724-6 · Cited by 55
Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma.
Liao, H., Huang, Y., Guo, B., Liang, B., Liu, X., Ou, H., Jiang, C., Li, X., & Yang, D. (2015) · Europe PMC (PubMed Central) · Cited by 54
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Mortensen, D. S., Fultz, K. E., Xu, S., Xu, W., Packard, G. K., Khambatta, G., Gamez, J. C., Leisten, J. C., Zhao, J., Apuy, J. L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1052 · Cited by 54
eIF4E Phosphorylation in Prostate Cancer
D'Abronzo, L. S., & Ghosh, P. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.003 · Cited by 56
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
Gu, W., Zou, H., Li, L., Carcedo, I. G., Xu, Z. P., & Monteiro, M. J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s100744 · Cited by 53
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas
Graillon, T., Defilles, C., Mohamed, A., Lisbonis, C., Germanetti, A. L., Chinot, O. L., Figarella-Branger, D. F., Roche, P.-H., Adetchessi, T., Fuentes, S., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1812-3 · Cited by 53
Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer
Browne, I. M., & Okines, A. F. C. (2024) · Cancers · doi:10.3390/cancers16122259 · Cited by 53
Discovery of Small-Molecule Selective mTORC1 Inhibitors via Direct Inhibition of Glucose Transporters
Kang, S. A., O’Neill, D. J., Machl, A. W., Lumpkin, C. J., Galda, S. N., Sengupta, S., Mahoney, S. J., Howell, J. J., Molz, L., Hahm, S., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.009 · Cited by 50
Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase
Sauer, H. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1230 · Cited by 49
Inhibition of Mammalian Target of Rapamycin With Rapamycin Reverses Hypertrophic Cardiomyopathy in Mice With Cardiomyocyte-Specific Knockout of PTEN
Xu, X., Roe, N. D., Weiser‐Evans, M. C. M., & Ren, J. T. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02526 · Cited by 49
microRNA regulation of cell viability and drug sensitivity in lung cancer
Du, L., & Pertsemlidis, A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.697149 · Cited by 49
Evolving Perspectives of mTOR Complexes in Immunity and Transplantation
Fantus, D., & Thomson, A. W. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13151 · Cited by 47
PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor
Bhattacharya, K., Maiti, S., & Mandal, C. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.34 · Cited by 46
Heightening Energetic Stress Selectively Targets LKB1-Deficient Non–Small Cell Lung Cancers
Momcilovic, M., McMickle, R., Abt, E., Seki, A., Simko, S. A., Magyar, C., Stout, D. B., Fishbein, M. C., Walser, T. C., Dubinett, S. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0797 · Cited by 46
“However, rapamycin as a single agent failed to induce a therapeutic response in theKras/Lkb1mousemodel of lung cancer and rapalogs have demonstrated limited benefit for NSCLC in the clinic (12, 13).”
New treatments for autosomal dominant polycystic kidney disease
Chang, M., & Ong, A. C. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12136 · Cited by 45
Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
Sulaiman, A., McGarry, S., Lam, K. M., El‐Sahli, S., Chambers, J., Kaczmarek, S., Li, L., Addison, C., Dimitroulakos, J., Arnaout, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0811-7 · Cited by 46
mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
Morrison, M. M., Young, C. D., Wang, S., Sobolik, T., Sanchez, V. M., Hicks, D. J., Cook, R. S., & Brantley‐Sieders, D. M. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005291 · Cited by 46
Translational control by oncogenic signaling pathways
Gao, B., & Roux, P. P. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.006 · Cited by 46
Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice
Giubellino, A., Bullova, P., Nölting, S., Turková, H., Powers, J. F., Liu, Q., Guichard, S. M., Tischler, A. S., Grossman, A. B., & Pacák, K. (2013) · Endocrinology · doi:10.1210/en.2012-1854 · Cited by 50
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects
Granata, S., Gassa, A. D., Carraro, A., Brunelli, M., Stallone, G., Lupo, A., & Zaza, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050735 · Cited by 45
Cellular adaptation to nutrient deprivation: crosstalk between the mTORC1 and eIF2α signaling pathways and implications for autophagy
Wengrod, J., & Gardner, L. B. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1056947 · Cited by 46
Prenatal Rapamycin Results in Early and Late Behavioral Abnormalities in Wildtype C57Bl/6 Mice
Tsai, P. T., Greene-Colozzi, E. A., Goto, J., Anderl, S., Kwiatkowski, D. J., & Şahin, M. (2012) · Behavior Genetics · doi:10.1007/s10519-012-9571-9 · Cited by 44
Chronic mTOR activation promotes cell survival in Merkel cell carcinoma
Lin, Z., McDermott, A., Shao, L., Kannan, A., Morgan, M., Stack, B. C., Moreno, M. A., Davis, D. A., Cornelius, L. A., & Gao, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.005 · Cited by 46
Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism
Xin, Y., & Cai, H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1024-z · Cited by 44
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy
He, S., Li, Q., Jiang, X., Lü, X., Feng, F., Qu, W., Chen, Y., & Sun, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01019 · Cited by 45
mTOR Inhibition Role in Cellular Mechanisms
Zaza, G., Granata, S., Caletti, C., Signorini, L. F., Stallone, G., & Lupo, A. (2018) · Transplantation · doi:10.1097/tp.0000000000001806 · Cited by 46
The Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 48
Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression
Parvani, J. G., Davuluri, G., Wendt, M. K., Espinosa, C., Tian, M., Danielpour, D., Sossey‐Alaoui, K., & Schiemann, W. P. (2015) · Neoplasia · doi:10.1016/j.neo.2015.02.003 · Cited by 43
Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways
Gu, W., Chen, J., Shao, R., Li, L., & Xu, Z. P. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61633 · Cited by 43
Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer
Kiyohara, Y., Yoshino, K., Kubota, S., Okuyama, H., Endo, H., Ueda, Y., Kimura, T., Kimura, T., Kamiura, S., & Inoue, M. (2016) · Cancer Science · doi:10.1111/cas.12898 · Cited by 44
Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation
Su, L., Liu, L., Jia, Y., Lei, L., Liu, J., Zhu, S., Zhou, H., Chen, R.-Y., Lu, H., & Yang, B. (2017) · Kidney International · doi:10.1016/j.kint.2017.04.013 · Cited by 43
Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss
Fu, X., Li, P., Zhang, L., Song, Y., An, Y., Zhang, A., Liu, W., Ye, C., Zhang, Y., Yue, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107357119 · Cited by 45
Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Hisamatsu, T., Mabuchi, S., Matsumoto, Y., Kawano, M., Sasano, T., Takahashi, R., Sawada, K., Ito, K., Kurachi, H., Schilder, R. J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1185 · Cited by 43
The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT–mTOR signaling pathway
Zhou, W., He, M.-R., Jiao, H., He, L., Deng, D., Cai, J., Xiao, Z., Ye, Y., Ding, Y., Liao, W., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.004 · Cited by 42
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Mallya, S., Fitch, B. A., Lee, J. S., So, L., Janes, M. R., & Fruman, D. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088865 · Cited by 42
Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling
Guo, L., Zhou, B. O., Liu, Z., Xu, Y., Lü, H., Xia, M., Guo, E., Shan, W., Chen, G., & Wang, C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4984-3 · Cited by 42
Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
Li, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 43
Coupling between Nutrient Availability and Thyroid Hormone Activation
Lartey, L. J., Werneck-de-Castro, J. P., O-Sullivan, I., Unterman, T. G., & Bianco, A. C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665505 · Cited by 41
Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
Kannan, A., Lin, Z., Shao, Q., Zhao, S., Fang, B., Moreno, M. A., Vural, E. A., Stack, B. C., Suen, J. Y., Kannan, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5878 · Cited by 41
Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells
Chen, W., Pan, Y., Wang, S., Liu, Y., Chen, G., Zhou, L., Ni, W., Wang, A., & Lu, Y. (2017) · BMC Cancer · doi:10.1186/s12885-016-3038-y · Cited by 41
Anticancer Effect of Nemopilema nomurai Jellyfish Venom on HepG2 Cells and a Tumor Xenograft Animal Model
Lee, H., Bae, S. K., Kim, M., Pyo, M. J., Kim, M., Yang, S., Won, C.-K., Yoon, W. D., Han, C. H., Kang, C., et al. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/2752716 · Cited by 41
Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously
Hii, L., Chung, F. F., Soo, J. S.-S., Tan, B. S., Mai, C., & Leong, C. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05504-5 · Cited by 42
Translational remodeling by RNA ‐binding proteins and noncoding RNAs
Ho, J. J. D., Man, J. H. S., Schatz, J. H., & Marsden, P. A. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1647 · Cited by 45
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
Fouqué, A., Delalande, O., Jean, M., Castellano, R., Josselin, E., Malleter, M., Shoji, K. F., Mac, D. H., Rampanarivo, H., Collette, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00991 · Cited by 40
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
Zeng, Z., Wang, R., Qiu, Y. H., Mak, D. H. F., Coombes, K. R., Yoo, S. Y., Zhang, Q., Jessen, K., Liu, Y., Rommel, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10397 · Cited by 40
Mammalian target of rapamycin as a therapeutic target in osteoporosis
Shen, G., Ren, H. J., Qiu, T., Zhang, Z., Zhao, W., Yu, X., Huang, J., Tang, J., Liang, D., Yao, Z., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26161 · Cited by 41
Metformin: An Inhibitor of mTORC1 Signaling
Melnik, B. C., & Schmitz, G. (2014) · Cited by 39
High glucose induces autophagy of MC3T3-E1 cells via ROS-AKT-mTOR axis
Wang, X., Feng, Z., Li, J., Chen, L., & Tang, W. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.036 · Cited by 39
Macropinocytosis and autophagy crosstalk in nutrient scavenging
Florey, O., & Overholtzer, M. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0154 · Cited by 39
An Anti‐Cancer Drug Candidate OSI‐027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms
Rehan, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26117 · Cited by 39
Biomarker‐driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum‐based chemotherapy
Park, S., Shim, J., Mortimer, P. G. S., Smith, S. A., Godin, R. E., Hollingsworth, S. J., Kim, H., Jung, H. A., Sun, J., Park, W., et al. (2020) · Cancer · doi:10.1002/cncr.33048 · Cited by 38
Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
Sun, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100847 · Cited by 38
Activate or Inhibit? Implications of Autophagy Modulation as a Therapeutic Strategy for Alzheimer’s Disease
Krishnan, S., Shrestha, Y., Jayatunga, D. P. W., Rea, S. L., Martins, R. N., & Bharadwaj, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186739 · Cited by 38
Differential ERK activation during autophagy induced by europium hydroxide nanorods and trehalose: Maximum clearance of huntingtin aggregates through combined treatment
Wei, P., Jin, P., Barui, A. K., Hu, Y. B., Zhang, L., Zhang, J., Shi, S.-S., Zhang, H., Lin, J., Zhou, W., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.006 · Cited by 36
mTORC2 promotes cell survival through c-Myc–dependent up-regulation of E2F1
Zou, Z., Chen, J., Liu, A., Zhou, X., Song, Q., Jia, C., Chen, Z., Lin, J., Yang, C., Li, M., et al. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201411128 · Cited by 36
Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches
Rehan, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219180 · Cited by 36
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration
Jin, J., & Zhao, Q. (2020) · Theranostics · doi:10.7150/thno.45219 · Cited by 37
PI3Kδ Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein-Barr Virus (EBV)+ B Cell Lymphomas
Furukawa, S., Wei, L., Krams, S., Esquivel, C., & Martinez, O. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12328 · Cited by 36
Hypoxia as a target for drug combination therapy of liver cancer
Bowyer, C. J., Lewis, A. L., Lloyd, A. W., Phillips, G. J., & Macfarlane, W. M. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000516 · Cited by 35
Effect of β‑ecdysterone on glucocorticoid‑induced apoptosis and autophagy in osteoblasts
Tang, Y., Yue, Z., Li, G., Zeng, L., Xin, D., Hu, Z., & Xu, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7840 · Cited by 36
Reappraisal to the study of 4E-BP1 as an mTOR substrate – A normative critique
Batool, A., Aashaq, S., & Andrabi, K. I. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.03.013 · Cited by 38
Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
Lv, X., Ma, X., & Hu, Y. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.800479 · Cited by 34
Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways
Selvarajah, J., Nathawat, K., Moumen, A., Ashcroft, M. A., & Carroll, V. A. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.395 · Cited by 34
A curated census of autophagy-modulating proteins and small molecules
Lorenzi, P. L., Claerhout, S., Mills, G. B., & Weinstein, J. N. (2014) · Autophagy · doi:10.4161/auto.28773 · Cited by 35
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
Beagle, B. R., Nguyen, D. M., Mallya, S., Tang, S. S. K., Lu, M., Zeng, Z., Konopleva, M. Y., Vo, T.-T. T., & Fruman, D. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2992 · Cited by 35
Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells
Shin, S. H., Lee, J. S., Zhang, J., Choi, S., Bošković, Ž., Zhao, R., Song, M., Wang, R., Tian, J., Lee, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9131 · Cited by 35
Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress
Doscas, M. E., Williamson, A. J., Usha, L., Bogachkov, Y. Y., Rao, G., Xiao, F., Wang, Y., Ruby, C. E., Kaufman, H. L., Zhou, J., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.08.006 · Cited by 33
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms
Durán, I., Goebell, P. J., Papazisis, K. T., Ravaud, A., Weichhart, T., Rodríguez-Portal, J. A., & Budde, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.888056 · Cited by 33
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Yi, Z., Ma, F., Liu, B., Guan, X., Li, L., Li, C., Qian, H., & Xu, B. (2019) · BMC Cancer · doi:10.1186/s12885-019-5668-3 · Cited by 33
Mechanistic Target of Rapamycin (mTOR) Inhibitors
Wang, D., & Eisen, H. J. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_553 · Cited by 33
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
Hsueh, Y., Chang, H. H., Chiang, N., Yen, C., Li, C., & Chen, L. (2014) · Oncotarget · doi:10.18632/oncotarget.2607 · Cited by 32
RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma
Lu, Z., Shi, X., Gong, F., Li, S., Wang, Y., Ren, Y., Zhang, M.-Y., Yu, B., Li, Y., Zhao, W. H., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.010 · Cited by 32

Authors: Wander, S. A., Hennessy, B. T., & Slingerland, J. M.
Affiliations: University of Miami (US)
Royal College of Surgeons in Ireland (IE)
Corresponding author: Slingerland, Joyce M.
ORCID: Wander, Seth A.
Hennessy, Bryan T.
Slingerland, Joyce M.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2011-04-01
Volume: 121
Issue: 4
Pages: 1231-1241
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci44145
PMC: PMC3069769
OpenAlex: W2025935112
Cited by: 427
References: 157
Citations by year: 2026: 7 · 2025: 17 · 2024: 10 · 2023: 18 · 2022: 16 · 2021: 14 · 2020: 23 · 2019: 23 · 2018: 27 · 2017: 39 · 2016: 28 · 2015: 63 · 2014: 51 · 2013: 47 · 2012: 28
FWCI: 4.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders: Doris Duke Charitable Foundation
National Institutes of Health (5-R01-)
National Cancer Institute (5-R01-CA-105118-04, R01CA105118)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: mTOR inhibitors, mTOR signaling, mTORC1, mTORC2, PI3K-related kinases, cancer therapy, therapeutic target
MeSH terms: Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents, Clinical Trials as Topic, Female, Humans, Male, Neoplasms, Transcription Factors, Signal Transduction, Phosphatidylinositol 3-Kinases, Sirolimus, Tumor Suppressor Proteins, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks